The aim of the work was to determine the clinical safety and immunogenicity of immunoadjuvant vaccines against influenza (MonoGripol Plus and Grippol® Plus) in 182 pregnant women in the II and III trimesters of gestation, and further assessment of fetal conditions and infants of the first 6 months of life. Results: It was shown that immunoadjuvant vaccines do not have a negative effect on the physiological course of pregnancy and the functional state of the fetoplacental complex. In the early postpartum period, the rates of physical and neuro-psychological development and the nature of feeding of children did not differ from the control group. In pregnant women vaccinated with Grippol® plus, the levels of seroprotection to strains of A/H1N1/v are 82.0%, A/H3N2/—88.0%, B—88.3% that measure the CPMP criteria and last more than a year . After birth, transplacental antibodies in children in protective values were observed in 52.3–68.9% of cases, did not differ from the control group, and disappear after 6 months. Respiratory infections during the first 6 months of life of infants born from mothers vaccinated against influenza registered in 1.8 times less frequently.
Part of the book: Vaccines